Menveo is a quadrivalent conjugated vaccine containing the Neisseria meningitidis serogroups A, C, Y and W-135. The presence of serum bactericidal antibodies protects against invasive meningococcal disease. Vaccination with Menveo leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.

Menveo is specifically indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. in persons 11 to 55 years of age.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Menveo
  • Adverse events associated with the use of Menveo may include, but are not limited to, the following:

    pain at the injection site
    headache
    myalgia
    malaise
    nausea
  • Menveo is supplied as a solution for intramuscular injection. Following reconstitution, Menveo should be administered as a single 0.5mL intramuscular injection, preferably into the deltoid muscle (upper arm).